Patients with isolated ZIC4 antibodies usually have paraneoplastic cerebellar degeneration (PCD) and small cell lung cancer (SCLC) but the frequency is unknown. We analyzed the presence of ZIC1, ZIC2 and ZIC4 antibodies in 27 patients with PCD and SCLC negative for other onconeural antibodies. ZIC antibodies were detected in nitrocellulose filters with phage plaques. Four (15%) PCD sera recognized ZIC2. Three of these positive sera also reacted with ZIC1 and two with ZIC4. Our study suggests that 1) the incidence of isolated ZIC antibodies is low in PCD patients and SCLC and 2) ZIC antibodies are probably directed to epitopes shared by the three ZIC proteins.
Introduction
Around 50% of patients with paraneoplastic cerebellar degeneration (PCD) and small cell lung carcinoma (SCLC) do not harbor onconeural or voltage-gated calcium channel antibodies (Graus et al., 2002 ) and the diagnosis is based on the clinical picture and demonstration of the tumor (Graus et al., 2004) . Immunity against ZIC (derived from zinc fingers of the cerebellum) proteins is common in patients with SCLC (Güre et al., 2000) . The ZIC family includes five DNA-binding proteins that are structurally similar to each other (Grinberg and Millen, 2005) . We previously found ZIC4 antibodies in 49 (29%) of 167 patients with paraneoplastic neurological syndromes and SCLC whereas the frequency of ZIC4 antibodies in patients with SCLC alone was significatively lower (16%) (Bataller et al., 2004) . Most of the patients with ZIC4 antibodies also had Hu or CV2 antibodies and presented with different paraneoplastic neurological syndromes. In contrast, eight of the nine patients with isolated ZIC4 antibodies presented with PCD (Bataller et al., 2004) . However, the frequency of antibodies against ZIC4 or other members of the ZIC family in PCD associated with SCLC is unknown. In the present study, we analyze the presence of antibodies against ZIC1, ZIC2 and ZIC4 in a series of PCD patients and SCLC to ascertain its value in the diagnosis of this disorder.
Materials and methods

Patients
We selected from our database, 27 patients with the final diagnosis of PCD with SCLC and no onconeural antibodies. The inclusion criteria were the presence of an isolated or clearly predominant cerebellar syndrome of unknown cause, the diagnosis of SCLC, and absence of onconeural antibodies. Serum and CSF, when available, were evaluated for the presence of onconeural antibodies (Hu, Yo, Ri, CV2, Tr, amphiphysin, Ma2, ANNA3, PCA2) by immunohistochemistry
